Our goal is to join community-based providers and academic oncologists to improve the care and outcomes of patients with hematologic malignancies. To reach this goal, the 7th Annual Updates from ASH 2021: Practice Changing Abstracts will address early treatment options and medical advances that can be implemented to reduce cancer-related deaths, including CAR T-cell therapy and novel therapeutics for the state-of-the-art  management of newly-diagnosed and relapsed blood cancers. Our overarching goal is to keep all healthcare professionals who care for patients with hematologic malignancies to stay abreast of the latest scientific updates, innovative ideas, and timeliest issues related to their care. This conference will provide the target audience with information that can help improve patient management and care strategies. Participants will discuss with content experts rapidly evolving developments, discover new treatments for patients, and improve overall practice paradigms. We will educate and empower community-based oncologists on best practices for treating hematologic cancers and inform them of the indicators for when to refer a patient for expert quaternary level care for advanced cellular therapies.

TARGETED AUDIENCE

This activity is designed for primary care physicians, hematologists, pathologists, medical oncologists, resident and fellow trainees, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals dedicated to the treatment of hematologic cancers.

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, participants will be able to:

• Illustrate how cutting-edge data presented at the 2021 Annual Meeting of the American Society of Hematology (ASH) can apply to clinical practice, addressing best practices and guidelines
• State the emerging treatment strategies for patients with low- and high-risk myeloid malignancies
• Discuss the optimal patient selection, timing, and regimen for transplant
• Evaluate clinical trial data in the context of cellular CAR T-cell therapy and its place in evolving hematologic malignancy treatment standards
• Choose the optimal treatment, sequencing, and supportive care strategies for patients with lymphoma using evidence-based guidelines
• Identify methods for integrating therapeutic advances such as CAR-T therapies idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) into practice for       myeloma patient care;
• Describe the pathogenesis, diagnostic evaluation and therapeutic modalities available for common benign hematologic diseases and COVID-associated hematologic diseases.

ACCREDITATION

The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.